Oramed Pharmaceuticals has developed a proprietary platform technology that allows for the oral delivery of drugs currently administered only via injection. The company's flagship product is an oral insulin capsule that has the potential to better the lives of millions of diabetics worldwide by enabling patients with type 2 diabetes to begin insulin therapy earlier, without needles. Oramed's oral insulin is in advanced phase 3 clinical trials under the US FDA and the European EMA for the treatment of type 2 diabetes. In addition to oral insulin, the company's proprietary POD technology can potentially be used to orally administer a number of protein-based therapies that are presently available only via injection.